Clinical Trial Update: Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tivantinib plus erlotinib vs placebo plus erlotinib in non-squamous non-small-cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• tivantinib (tivantinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non Squamous, Non-small-cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2020-10-30